Covaxin has been granted restricted emergency use authorization by the Drugs Controller General of India (DCGI) for children aged 6 to 12.
The Drug Controller General of India (DCGI) has directed Hyderabad-based pharmaceutical business Bharat Biotech to submit safety data, including data on adverse occurrences, with due analysis every 15 days for the first two months and monthly afterwards for up to five months, according to sources. According to reports, the DCGI will shortly provide emergency use authorization for Corbevax COVID-19 vaccinations for children aged 5 to 12.
On Thursday, the DCGI’s Subject Expert Committee (SEC) endorsed the limited emergency use of Biological E’s Corbevax COVID-19 vaccination for children aged 5 to 12.
The topic expert committee has requested further data from BharatBiotech for Covaxin in children under the age of 12 years. According to sources, no recommendations have been made as of yet.
Corbevax is now being provided to youngsters aged 12 to 14.
COVID-19 immunizations for minors in India began on January 3rd, with those aged 15 to 18 receiving Bharat Biotech’s Covaxin.
On March 16, the drive was expanded to include youngsters over the age of 12 for Corbevax.
In India, two COVID-19 vaccinations are now being administered to children over the age of 12.
Meanwhile, Union Health Minister Mansukh Mandaviya tweeted about the DCGI’s approval of Covaxin for the 6–12 age group and Corbevax for the 5–12 age group, saying, “India’s fight against COVID becomes stronger @CDSCO In India, the INF recommends “Covaxin” for children aged 6–12 and “Corbevax” for children aged 5–12 for “Restricted Use in Emergencies.”